Healthy Extracts Sees First Half 2026 Net Revenue Up More Than 93% to Record $3.6 Million+

Healthy Extracts expects Q2 2026 net revenue to exceed $2.0M (+112% sequentially, +129% YoY) and first-half 2026 net revenue to top $3.6M+ (+93% vs. 1H 2025). Growth is attributed to the October 2025 merger with Gummy USA and the May 2026 acquisition of Imaraïs Beauty, including an initial nearly 4M-gummy order shipping to 4,000+ stores. Management reaffirmed the potential for annualized net revenue of over $20M by year-end (~3x last year), supported by precision-dose manufacturing and expanding B2B/retail channels.

Analysis

The real signal here is not the revenue print; it is that HYEX appears to be converting brand access into manufacturing throughput. In this corner of consumer health, the equity only rerates if volume becomes repeatable and cash-generative, so the first thing to watch is whether retail-door expansion turns into sustained reorder cadence rather than one-off launch fills. If that happens, the manufacturing subsidiary gains a second business model: lower-risk contract production layered on top of owned brands, which is a better multiple story than a pure promo-driven consumer brand.

Second-order effects matter more than the headline growth rate. Target and Ulta function as channel validators, but they also raise the bar on service levels, inventory funding, and margin discipline; if HYEX is financing growth through working capital, the apparent momentum can reverse quickly. The likely losers are legacy nutraceutical names without differentiated dose technology or retail pull, because HYEX can use a celebrity-led brand as a wedge to win shelf space and then sell adjacent B2B production capacity into the same network.

The main risk is that the base is still too small for the market to underwrite the growth narrative without visible gross-margin expansion and operating cash flow. Over the next 30-90 days, the 10-Q is the catalyst: if it shows revenue concentration, dilution, or weak cash conversion, the stock likely gives back most of the promotional move. Over 6-18 months, the thesis is falsified if the order book does not broaden beyond a few SKUs and if the company cannot prove that the acquired brand and manufacturing asset improve economics rather than just top-line optics.

Key Decisions for Investors

• Speculative long HYEX only, sized as a high-beta event position, into the 10-Q; reward is a potential rerating if repeat orders and margin expansion show up, but position size should reflect dilution and OTC liquidity risk.
• Set a hard watch item on HYEX's gross margin and operating cash flow in the next filing; exit or fade the move if revenue growth is not accompanied by clear cash conversion and lower customer concentration.
• No direct trade in TGT or ULTA on this headline; treat them as channel validators only, and revisit if suppliers or shelf-space disclosures later show measurable assortment expansion.
• Relative-value idea: long HYEX vs short a legacy wellness/supplement small cap like NPHC only if you want to express manufacturing/brand optionality; this is a high-risk pair and should be abandoned if HYEX loses momentum after the filing.
• For traders who cannot tolerate OTC liquidity, stay on the sidelines and wait for proof of recurring revenue in two consecutive quarters; the first move is likely promotional, the second is what determines whether the stock can sustain a higher base.